[SCHEDULE 13D/A] Marker Therapeutics, Inc. SEC Filing
Amendment No. 2 to a Schedule 13D reports that John R. Wilson, as trustee of the John R. Wilson Revocable Trust U/A DTD 08/03/2017, now beneficially owns 641,801 shares of Marker Therapeutics, Inc. common stock, representing 4.96% of the 12,938,910 shares outstanding as of August 4, 2025. The filing states the decrease to below 5% resulted from sales summarized on Schedule A. The trustee has sole voting and dispositive power over the reported shares, the source of funds is identified as OO (other), and Mr. Wilson resigned from the Issuer鈥檚 board on January 24, 2025. The statement is signed by John R. Wilson as trustee on August 20, 2025.
Emendamento n. 2 a un Modulo 13D segnala che John R. Wilson, in qualit脿 di fiduciario del John R. Wilson Revocable Trust U/A DTD 08/03/2017, detiene ora in via beneficiaria 641.801 azioni ordinarie di Marker Therapeutics, Inc., pari a 4,96% delle 12.938.910 azioni in circolazione al 4 agosto 2025. Il deposito indica che la riduzione al di sotto del 5% 猫 dovuta a vendite riepilogate nell'Allegato A. Il fiduciario mantiene il completo potere di voto e di disposizione sulle azioni dichiarate, la fonte dei fondi 猫 indicata come OO (altro), e il sig. Wilson si 猫 dimesso dal consiglio dell'Emittente il 24 gennaio 2025. La dichiarazione 猫 firmata da John R. Wilson in qualit脿 di fiduciario il 20 agosto 2025.
Enmienda n.潞 2 al Schedule 13D informa que John R. Wilson, como fideicomisario del John R. Wilson Revocable Trust U/A DTD 08/03/2017, posee ahora de forma beneficiaria 641.801 acciones ordinarias de Marker Therapeutics, Inc., lo que representa el 4,96% de las 12.938.910 acciones en circulaci贸n a fecha del 4 de agosto de 2025. El documento indica que la disminuci贸n por debajo del 5% se produjo por ventas resumidas en el Anexo A. El fideicomisario tiene el poder exclusivo de voto y disposici贸n sobre las acciones notificadas, la fuente de los fondos se identifica como OO (otro), y el Sr. Wilson renunci贸 al consejo de la Emisora el 24 de enero de 2025. La declaraci贸n est谩 firmada por John R. Wilson como fideicomisario el 20 de agosto de 2025.
Schedule 13D鞚� 靾橃爼靹� 鞝�2順�電� John R. Wilson鞚� 2017雲� 8鞗� 3鞚检瀽 John R. Wilson Revocable Trust U/A DTD鞚� 靾橅儊鞛愲靹� 順勳灛 Marker Therapeutics, Inc. 氤错喌欤� 641,801欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 2025雲� 8鞗� 4鞚� 旮办 氚滍枆欤检嫕靾� 12,938,910欤� 欷� 4.96%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. 鞝滌稖靹滊電� 5% 氙鸽鞙茧 臧愳唽頃� 瓴冹澊 攵�靻嶌劀 A鞐� 鞖旍暯霅� 毵る弰 霑岆鞚措澕瓿� 氇呾嫓頃╇媹雼�. 靾橅儊鞛愲姅 氤搓碃霅� 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 臧�歆�瓿� 鞛堨溂氅�, 鞛愱笀 於滌矘電� 翱翱(旮绊俭)搿� 響滌嫓霅橃柎 鞛堦碃, Wilson 鞌姅 2025雲� 1鞗� 24鞚� 氚滍枆鞛愳潣 鞚挫偓須岇棎靹� 靷瀯頄堨姷雼堧嫟. 頃措嫻 歆勳垹靹滊姅 2025雲� 8鞗� 20鞚� 靾橅儊鞛� 鞛愱博鞙茧 John R. Wilson鞚� 靹滊獏頄堨姷雼堧嫟.
Avenant n掳2 au Schedule 13D indique que John R. Wilson, en tant que fiduciaire du John R. Wilson Revocable Trust U/A DTD 08/03/2017, poss猫de d茅sormais 脿 titre b茅n茅ficiaire 641 801 actions ordinaires de Marker Therapeutics, Inc., repr茅sentant 4,96% des 12 938 910 actions en circulation au 4 ao没t 2025. Le d茅p么t pr茅cise que la baisse en dessous de 5 % r茅sulte de ventes r茅capitul茅es 脿 l'Annexe A. Le fiduciaire d茅tient le pouvoir exclusif de vote et de disposition sur les actions d茅clar茅es, la source des fonds est indiqu茅e comme OO (autre), et M. Wilson a d茅missionn茅 du conseil d'administration de l'脡metteur le 24 janvier 2025. La d茅claration est sign茅e par John R. Wilson en tant que fiduciaire le 20 ao没t 2025.
脛nderung Nr. 2 zu einem Schedule 13D berichtet, dass John R. Wilson als Treuh盲nder des John R. Wilson Revocable Trust U/A DTD 08/03/2017 nun wirtschaftlich 641.801 Aktien der Stammaktien von Marker Therapeutics, Inc. h盲lt, was 4,96% der 12.938.910 ausstehenden Aktien zum 4. August 2025 entspricht. Die Einreichung gibt an, dass die Unterschreitung der 5%-Schwelle auf Verk盲ufe zur眉ckzuf眉hren ist, die in Anlage A zusammengefasst sind. Der Treuh盲nder besitzt die ausschlie脽liche Stimm- und Verf眉gungsgewalt 眉ber die gemeldeten Aktien, die Mittelherkunft ist als OO (sonstiges) angegeben, und Herr Wilson trat am 24. Januar 2025 aus dem Vorstand des Emittenten zur眉ck. Die Erkl盲rung ist von John R. Wilson in seiner Eigenschaft als Treuh盲nder am 20. August 2025 unterzeichnet.
- Clear disclosure of current beneficial ownership (641,801 shares) and precise percentage (4.96%)
- Maintained sole voting and dispositive power over the reported shares
- Reduction below 5% indicates divestment via sales (detailed on Schedule A) which may reduce influence
- No explanation in this amendment for the sales or intent, requiring reference to Exhibit A or prior amendment for context
Insights
TL;DR: Beneficial ownership fell below 5%, now 4.96% (641,801 shares); sales are documented on Schedule A.
The filing is a straightforward disclosure that the Reporting Person鈥檚 stake in MRKR dropped under the 5% reporting threshold. The key numeric facts are clear: 641,801 shares held and 12,938,910 shares outstanding used for the percentage calculation. The disclosure of sole voting and dispositive power means the trustee retains full control of this stake despite the reduction. No new purchases, control contests, or compensatory arrangements are disclosed here; the change is driven by sales detailed separately on Exhibit A.
TL;DR: Trustee reduced position below 5% and previously resigned from the board; no contractual arrangements disclosed in this amendment.
The filing confirms John R. Wilson鈥檚 role as trustee and his prior board resignation on January 24, 2025. The amendment does not identify any ongoing agreements, concerted actor groups, or special arrangements affecting governance rights. Sole voting power is maintained for the reported shares, and no litigation or legal encumbrances are disclosed. The governance implication is limited: ownership fell below the 5% public ownership threshold, triggering this amendment to update prior disclosures.
Emendamento n. 2 a un Modulo 13D segnala che John R. Wilson, in qualit脿 di fiduciario del John R. Wilson Revocable Trust U/A DTD 08/03/2017, detiene ora in via beneficiaria 641.801 azioni ordinarie di Marker Therapeutics, Inc., pari a 4,96% delle 12.938.910 azioni in circolazione al 4 agosto 2025. Il deposito indica che la riduzione al di sotto del 5% 猫 dovuta a vendite riepilogate nell'Allegato A. Il fiduciario mantiene il completo potere di voto e di disposizione sulle azioni dichiarate, la fonte dei fondi 猫 indicata come OO (altro), e il sig. Wilson si 猫 dimesso dal consiglio dell'Emittente il 24 gennaio 2025. La dichiarazione 猫 firmata da John R. Wilson in qualit脿 di fiduciario il 20 agosto 2025.
Enmienda n.潞 2 al Schedule 13D informa que John R. Wilson, como fideicomisario del John R. Wilson Revocable Trust U/A DTD 08/03/2017, posee ahora de forma beneficiaria 641.801 acciones ordinarias de Marker Therapeutics, Inc., lo que representa el 4,96% de las 12.938.910 acciones en circulaci贸n a fecha del 4 de agosto de 2025. El documento indica que la disminuci贸n por debajo del 5% se produjo por ventas resumidas en el Anexo A. El fideicomisario tiene el poder exclusivo de voto y disposici贸n sobre las acciones notificadas, la fuente de los fondos se identifica como OO (otro), y el Sr. Wilson renunci贸 al consejo de la Emisora el 24 de enero de 2025. La declaraci贸n est谩 firmada por John R. Wilson como fideicomisario el 20 de agosto de 2025.
Schedule 13D鞚� 靾橃爼靹� 鞝�2順�電� John R. Wilson鞚� 2017雲� 8鞗� 3鞚检瀽 John R. Wilson Revocable Trust U/A DTD鞚� 靾橅儊鞛愲靹� 順勳灛 Marker Therapeutics, Inc. 氤错喌欤� 641,801欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 2025雲� 8鞗� 4鞚� 旮办 氚滍枆欤检嫕靾� 12,938,910欤� 欷� 4.96%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頃╇媹雼�. 鞝滌稖靹滊電� 5% 氙鸽鞙茧 臧愳唽頃� 瓴冹澊 攵�靻嶌劀 A鞐� 鞖旍暯霅� 毵る弰 霑岆鞚措澕瓿� 氇呾嫓頃╇媹雼�. 靾橅儊鞛愲姅 氤搓碃霅� 欤检嫕鞐� 雽�頃� 雼弲 鞚橁舶甓� 氚� 觳橂秳甓�鞚� 臧�歆�瓿� 鞛堨溂氅�, 鞛愱笀 於滌矘電� 翱翱(旮绊俭)搿� 響滌嫓霅橃柎 鞛堦碃, Wilson 鞌姅 2025雲� 1鞗� 24鞚� 氚滍枆鞛愳潣 鞚挫偓須岇棎靹� 靷瀯頄堨姷雼堧嫟. 頃措嫻 歆勳垹靹滊姅 2025雲� 8鞗� 20鞚� 靾橅儊鞛� 鞛愱博鞙茧 John R. Wilson鞚� 靹滊獏頄堨姷雼堧嫟.
Avenant n掳2 au Schedule 13D indique que John R. Wilson, en tant que fiduciaire du John R. Wilson Revocable Trust U/A DTD 08/03/2017, poss猫de d茅sormais 脿 titre b茅n茅ficiaire 641 801 actions ordinaires de Marker Therapeutics, Inc., repr茅sentant 4,96% des 12 938 910 actions en circulation au 4 ao没t 2025. Le d茅p么t pr茅cise que la baisse en dessous de 5 % r茅sulte de ventes r茅capitul茅es 脿 l'Annexe A. Le fiduciaire d茅tient le pouvoir exclusif de vote et de disposition sur les actions d茅clar茅es, la source des fonds est indiqu茅e comme OO (autre), et M. Wilson a d茅missionn茅 du conseil d'administration de l'脡metteur le 24 janvier 2025. La d茅claration est sign茅e par John R. Wilson en tant que fiduciaire le 20 ao没t 2025.
脛nderung Nr. 2 zu einem Schedule 13D berichtet, dass John R. Wilson als Treuh盲nder des John R. Wilson Revocable Trust U/A DTD 08/03/2017 nun wirtschaftlich 641.801 Aktien der Stammaktien von Marker Therapeutics, Inc. h盲lt, was 4,96% der 12.938.910 ausstehenden Aktien zum 4. August 2025 entspricht. Die Einreichung gibt an, dass die Unterschreitung der 5%-Schwelle auf Verk盲ufe zur眉ckzuf眉hren ist, die in Anlage A zusammengefasst sind. Der Treuh盲nder besitzt die ausschlie脽liche Stimm- und Verf眉gungsgewalt 眉ber die gemeldeten Aktien, die Mittelherkunft ist als OO (sonstiges) angegeben, und Herr Wilson trat am 24. Januar 2025 aus dem Vorstand des Emittenten zur眉ck. Die Erkl盲rung ist von John R. Wilson in seiner Eigenschaft als Treuh盲nder am 20. August 2025 unterzeichnet.
FAQ
How many Marker Therapeutics (MRKR) shares does John R. Wilson鈥檚 trust now own?
What caused the change in reported ownership percentage in this Schedule 13D/A?
Does the trustee retain voting control over the MRKR shares?
When did John R. Wilson resign from the Issuer鈥檚 board?
What outstanding share count was used to calculate the 4.96% figure?
